1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,964 | 1,010 | 10:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| Mo | Tevogen Bio Inc: Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation | 74 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets... ► Artikel lesen | |
| 01.05. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 30.04. | Tevogen Bio Inc: CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment | 38 | GlobeNewswire (Europe) | WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that CD8 Technology Services LLC ("CD8") has signed a letter of intent... ► Artikel lesen | |
| 29.04. | Tevogen Bio shares surge on revenue forecast | 2 | Investing.com | ||
| 29.04. | Tevogen Bio-Aktien steigen nach Umsatzprognose | 3 | Investing.com Deutsch | ||
| 29.04. | Tevogen hebt Vorteile von DRS-Konten für Aktionäre hervor | 1 | Investing.com Deutsch | ||
| 29.04. | Tevogen highlights DRS account benefits for shareholders | 1 | Investing.com | ||
| 29.04. | Tevogen Bio Inc: Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts | 64 | GlobeNewswire (Europe) | WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today informed shareholders about several differences between holding shares in... ► Artikel lesen | |
| 28.04. | Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? | 5 | Benzinga.com | ||
| 28.04. | Tevogen shares skyrocket as it projects $1B in revenue for its oncology pipeline | 3 | Seeking Alpha | ||
| 28.04. | Tevogen Bio Inc: Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion | 64 | GlobeNewswire (Europe) | Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company's dedicated R&D... ► Artikel lesen | |
| 25.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | Tevogen Bio Inc: Tevogen Bio Announces 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 17.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.04. | Tevogen Bio Inc: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility | 113 | GlobeNewswire (Europe) | The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilitiesFormalized agreement aligns with previously announced topline forecasts WARREN, N.J., April... ► Artikel lesen | |
| 15.04. | Tevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction | 592 | GlobeNewswire (Europe) | WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics... ► Artikel lesen | |
| 09.04. | Tevogen Bio Inc: Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States | 103 | GlobeNewswire (Europe) | WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response... ► Artikel lesen | |
| 09.04. | Tevogen Bio Inc: Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs | 1 | GlobeNewswire (USA) | ||
| 07.04. | Tevogen reports high insider ownership amid market volatility | 1 | Investing.com |
Seite:
1 2 3 4 5 Weiter >>
86 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,180 | -0,80 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| AMGEN | 237,85 | +1,30 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| NOVAVAX | 5,336 | +0,08 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,085 | +14,98 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 515,00 | +0,59 % | Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock | ||
| INOVIO PHARMACEUTICALS | 1,710 | +1,18 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,020 | -0,66 % | COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,700 | -1,02 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 52,48 | -0,15 % | BioMarin Reports New Positive CANOPY Studies Data For Voxzogo | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data from studies of Voxzogo in children with achondroplasia and other skeletal conditions.Voxzogo is already... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,445 | +4,22 % | Breaking News: ExoPTEN auf der Weltbühne in Salt Lake City! | ||
| ARROWHEAD PHARMACEUTICALS | 13,450 | +0,64 % | Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum | ||
| XOMA ROYALTY | 24,800 | +3,33 % | XOMA Royalty GAAP EPS of $0.06, revenue of $15.91M | ||
| T2 BIOSYSTEMS | 0,104 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,850 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial | Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,97 % bei einem Aktienkurs von 0,924 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.